JP4986505B2 - 糖尿病性血管障害および呼吸障害予防および/または治療剤 - Google Patents
糖尿病性血管障害および呼吸障害予防および/または治療剤 Download PDFInfo
- Publication number
- JP4986505B2 JP4986505B2 JP2006145134A JP2006145134A JP4986505B2 JP 4986505 B2 JP4986505 B2 JP 4986505B2 JP 2006145134 A JP2006145134 A JP 2006145134A JP 2006145134 A JP2006145134 A JP 2006145134A JP 4986505 B2 JP4986505 B2 JP 4986505B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclohexenone
- cyclohexen
- methyl
- group
- diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000023504 respiratory system disease Diseases 0.000 title claims description 27
- 239000003814 drug Substances 0.000 title claims description 25
- 229940124597 therapeutic agent Drugs 0.000 title claims description 22
- 230000003449 preventive effect Effects 0.000 title claims description 11
- 208000013600 Diabetic vascular disease Diseases 0.000 title description 24
- 201000009101 diabetic angiopathy Diseases 0.000 title description 24
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 title description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims description 75
- -1 alcohol compound Chemical class 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 40
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 230000000069 prophylactic effect Effects 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 201000002859 sleep apnea Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- DOIURPHENDIWHZ-UHFFFAOYSA-N 3-(11-hydroxyundecyl)-4,4-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CCC(=O)C=C1CCCCCCCCCCCO.CC1(C)CCC(=O)C=C1CCCCCCCCCCCO DOIURPHENDIWHZ-UHFFFAOYSA-N 0.000 claims description 3
- LNLDEQMMWBLOOE-UHFFFAOYSA-N 3-(11-hydroxyundecyl)cyclohex-2-en-1-one Chemical compound OCCCCCCCCCCCC1=CC(=O)CCC1.OCCCCCCCCCCCC1=CC(=O)CCC1 LNLDEQMMWBLOOE-UHFFFAOYSA-N 0.000 claims description 3
- UNNNLVVXTUETAT-UHFFFAOYSA-N 3-(12-hydroxydodecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCO)C(C)(C)CCC1=O UNNNLVVXTUETAT-UHFFFAOYSA-N 0.000 claims description 3
- ZPXDAIMVDRZMFO-UHFFFAOYSA-N 3-(12-hydroxydodecyl)-2-methylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCO)CCCC1=O.CC1=C(CCCCCCCCCCCCO)CCCC1=O ZPXDAIMVDRZMFO-UHFFFAOYSA-N 0.000 claims description 3
- VWHBXCMHCQZEIM-UHFFFAOYSA-N 3-(12-hydroxydodecyl)-4-methylcyclohex-2-en-1-one Chemical compound CC1CCC(=O)C=C1CCCCCCCCCCCCO.CC1CCC(=O)C=C1CCCCCCCCCCCCO VWHBXCMHCQZEIM-UHFFFAOYSA-N 0.000 claims description 3
- UHKZSFHPUKLKBL-UHFFFAOYSA-N 3-(12-hydroxydodecyl)cyclohex-2-en-1-one Chemical compound OCCCCCCCCCCCCC1=CC(=O)CCC1.OCCCCCCCCCCCCC1=CC(=O)CCC1 UHKZSFHPUKLKBL-UHFFFAOYSA-N 0.000 claims description 3
- ULDATRKHJHQBTR-UHFFFAOYSA-N 3-(13-hydroxytridecyl)-2-methylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCCO)CCCC1=O.CC1=C(CCCCCCCCCCCCCO)CCCC1=O ULDATRKHJHQBTR-UHFFFAOYSA-N 0.000 claims description 3
- OREBVOMOGKPLDE-UHFFFAOYSA-N 3-(13-hydroxytridecyl)-4-methylcyclohex-2-en-1-one Chemical compound CC1CCC(=O)C=C1CCCCCCCCCCCCCO.CC1CCC(=O)C=C1CCCCCCCCCCCCCO OREBVOMOGKPLDE-UHFFFAOYSA-N 0.000 claims description 3
- AOBYGRMOODZXQR-UHFFFAOYSA-N 3-(13-hydroxytridecyl)cyclohex-2-en-1-one Chemical compound OCCCCCCCCCCCCCC1=CC(=O)CCC1.OCCCCCCCCCCCCCC1=CC(=O)CCC1 AOBYGRMOODZXQR-UHFFFAOYSA-N 0.000 claims description 3
- AUVJWNSTFOQVLH-UHFFFAOYSA-N 3-(14-hydroxytetradecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCCCO)C(C)(C)CCC1=O.CC1=C(CCCCCCCCCCCCCCO)C(C)(C)CCC1=O AUVJWNSTFOQVLH-UHFFFAOYSA-N 0.000 claims description 3
- WGYYPVLUFJWZMY-UHFFFAOYSA-N 3-(14-hydroxytetradecyl)-4,4-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CCC(=O)C=C1CCCCCCCCCCCCCCO.CC1(C)CCC(=O)C=C1CCCCCCCCCCCCCCO WGYYPVLUFJWZMY-UHFFFAOYSA-N 0.000 claims description 3
- BBGPBJVKPRRQLY-UHFFFAOYSA-N 3-(14-hydroxytetradecyl)cyclohex-2-en-1-one Chemical compound OCCCCCCCCCCCCCCC1=CC(=O)CCC1.OCCCCCCCCCCCCCCC1=CC(=O)CCC1 BBGPBJVKPRRQLY-UHFFFAOYSA-N 0.000 claims description 3
- AYYFNUGVHYVARL-UHFFFAOYSA-N 3-(16-hydroxyhexadecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCCCCCO)C(C)(C)CCC1=O.CC1=C(CCCCCCCCCCCCCCCCO)C(C)(C)CCC1=O AYYFNUGVHYVARL-UHFFFAOYSA-N 0.000 claims description 3
- RMKZULPNDHRAGK-UHFFFAOYSA-N CC1(C)CCC(=O)C=C1CCCCCCCCCCCCCO.CC1(C)CCC(=O)C=C1CCCCCCCCCCCCCO Chemical compound CC1(C)CCC(=O)C=C1CCCCCCCCCCCCCO.CC1(C)CCC(=O)C=C1CCCCCCCCCCCCCO RMKZULPNDHRAGK-UHFFFAOYSA-N 0.000 claims description 3
- NXDWXPZSXDBXEQ-UHFFFAOYSA-N CC1(C)CCC(=O)C=C1CCCCCCCCCCCCO.CC1(C)CCC(=O)C=C1CCCCCCCCCCCCO Chemical compound CC1(C)CCC(=O)C=C1CCCCCCCCCCCCO.CC1(C)CCC(=O)C=C1CCCCCCCCCCCCO NXDWXPZSXDBXEQ-UHFFFAOYSA-N 0.000 claims description 3
- RGEAPRLPPVRDPZ-UHFFFAOYSA-N CC1=C(CCCCCCCCCCCCCCCO)C(C)(C)CCC1=O.CC1=C(CCCCCCCCCCCCCCCO)C(C)(C)CCC1=O Chemical compound CC1=C(CCCCCCCCCCCCCCCO)C(C)(C)CCC1=O.CC1=C(CCCCCCCCCCCCCCCO)C(C)(C)CCC1=O RGEAPRLPPVRDPZ-UHFFFAOYSA-N 0.000 claims description 3
- BETWFLWYZIUGMT-UHFFFAOYSA-N CC1=C(CCCCCCCCCCCCCCO)CCCC1=O.CC1=C(CCCCCCCCCCCCCCO)CCCC1=O Chemical compound CC1=C(CCCCCCCCCCCCCCO)CCCC1=O.CC1=C(CCCCCCCCCCCCCCO)CCCC1=O BETWFLWYZIUGMT-UHFFFAOYSA-N 0.000 claims description 3
- GDNYPABRYUUURS-UHFFFAOYSA-N CC1CCC(=O)C=C1CCCCCCCCCCCCCCO.CC1CCC(=O)C=C1CCCCCCCCCCCCCCO Chemical compound CC1CCC(=O)C=C1CCCCCCCCCCCCCCO.CC1CCC(=O)C=C1CCCCCCCCCCCCCCO GDNYPABRYUUURS-UHFFFAOYSA-N 0.000 claims description 3
- SFVHKFQCLLSKRQ-UHFFFAOYSA-N CC1CCC(=O)C=C1CCCCCCCCCCCO.CC1CCC(=O)C=C1CCCCCCCCCCCO Chemical compound CC1CCC(=O)C=C1CCCCCCCCCCCO.CC1CCC(=O)C=C1CCCCCCCCCCCO SFVHKFQCLLSKRQ-UHFFFAOYSA-N 0.000 claims description 3
- BICDKMCGMFBKND-UHFFFAOYSA-N OCCCCCCCCCCC1=CC(CCC1C)=O.OCCCCCCCCCCC1=CC(CCC1C)=O Chemical compound OCCCCCCCCCCC1=CC(CCC1C)=O.OCCCCCCCCCCC1=CC(CCC1C)=O BICDKMCGMFBKND-UHFFFAOYSA-N 0.000 claims description 3
- REKKCYFYHBLAQD-UHFFFAOYSA-N 3-(11-hydroxyundecyl)-2-methylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCO)CCCC1=O REKKCYFYHBLAQD-UHFFFAOYSA-N 0.000 claims description 2
- KWDRAQJHUWWKEA-UHFFFAOYSA-N 3-(13-hydroxytridecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCCO)C(C)(C)CCC1=O KWDRAQJHUWWKEA-UHFFFAOYSA-N 0.000 claims description 2
- PWCDZZMAWNQTMA-UHFFFAOYSA-N CC1(C(=CC(CC1)=O)CCCCCCCCCCO)C.CC1(C(=CC(CC1)=O)CCCCCCCCCCO)C Chemical compound CC1(C(=CC(CC1)=O)CCCCCCCCCCO)C.CC1(C(=CC(CC1)=O)CCCCCCCCCCO)C PWCDZZMAWNQTMA-UHFFFAOYSA-N 0.000 claims description 2
- GFUHAWPQFNYKOF-UHFFFAOYSA-N OCCCCCCCCCCC1=CC(CCC1)=O.OCCCCCCCCCCC1=CC(CCC1)=O Chemical compound OCCCCCCCCCCC1=CC(CCC1)=O.OCCCCCCCCCCC1=CC(CCC1)=O GFUHAWPQFNYKOF-UHFFFAOYSA-N 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 62
- 238000004519 manufacturing process Methods 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 31
- 238000004809 thin layer chromatography Methods 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 241000700159 Rattus Species 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 20
- 229940125961 compound 24 Drugs 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
- 230000004118 muscle contraction Effects 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- 208000011338 SATB2 associated disease Diseases 0.000 description 14
- 208000013959 SATB2-associated syndrome Diseases 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 210000000981 epithelium Anatomy 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- LQANGKSBLPMBTJ-BRSNVKEHSA-N (z)-7-[(1s,2s,3r,4r)-3-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid Chemical compound C1[C@@H]2CO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O LQANGKSBLPMBTJ-BRSNVKEHSA-N 0.000 description 7
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
- 229960004484 carbachol Drugs 0.000 description 7
- 210000003038 endothelium Anatomy 0.000 description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002464 muscle smooth vascular Anatomy 0.000 description 7
- 229960001052 streptozocin Drugs 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 6
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- CHLCPTJLUJHDBO-UHFFFAOYSA-M sodium;benzenesulfinate Chemical compound [Na+].[O-]S(=O)C1=CC=CC=C1 CHLCPTJLUJHDBO-UHFFFAOYSA-M 0.000 description 5
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 5
- 208000019553 vascular disease Diseases 0.000 description 5
- LGZMUUBPTDRQQM-UHFFFAOYSA-N 10-Bromo-1-decanol Chemical compound OCCCCCCCCCCBr LGZMUUBPTDRQQM-UHFFFAOYSA-N 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000008960 Diabetic foot Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011513 continuous positive airway pressure therapy Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002736 metal compounds Chemical class 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 3
- 229950005741 rolipram Drugs 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 230000009284 tracheal contraction Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- IMUKUASQDQPYGV-UHFFFAOYSA-N 10-[7-(benzenesulfonyl)-6-methyl-1,4-dioxaspiro[4.5]decan-7-yl]decan-1-ol Chemical compound C1CCC(S(=O)(=O)C=2C=CC=CC=2)(CCCCCCCCCCO)C(C)C21OCCO2 IMUKUASQDQPYGV-UHFFFAOYSA-N 0.000 description 2
- SGJGOUFOTIUOKU-UHFFFAOYSA-N 10-[7-(benzenesulfonyl)-8,8-dimethyl-1,4-dioxaspiro[4.5]decan-7-yl]decan-1-ol Chemical compound C1C(S(=O)(=O)C=2C=CC=CC=2)(CCCCCCCCCCO)C(C)(C)CCC21OCCO2 SGJGOUFOTIUOKU-UHFFFAOYSA-N 0.000 description 2
- NZGSTCKVQKBABW-UHFFFAOYSA-N 10-[7-(benzenesulfonyl)-8-methyl-1,4-dioxaspiro[4.5]decan-7-yl]decan-1-ol Chemical compound C1C(S(=O)(=O)C=2C=CC=CC=2)(CCCCCCCCCCO)C(C)CCC21OCCO2 NZGSTCKVQKBABW-UHFFFAOYSA-N 0.000 description 2
- GYVUGCMWJRCNIG-UHFFFAOYSA-N 12-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)dodecyl acetate Chemical compound CC(=O)OCCCCCCCCCCCCC1=C(C)C(=O)CCC1(C)C GYVUGCMWJRCNIG-UHFFFAOYSA-N 0.000 description 2
- RXWVWPVPAIVQPP-UHFFFAOYSA-N 3-(10-hydroxydecyl)-4,4-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CCC(=O)C=C1CCCCCCCCCCO RXWVWPVPAIVQPP-UHFFFAOYSA-N 0.000 description 2
- LKOHCUYBNLXSCN-UHFFFAOYSA-N 3-(benzenesulfonyl)-2-methylcyclohexan-1-one Chemical compound C1CCC(=O)C(C)C1S(=O)(=O)C1=CC=CC=C1 LKOHCUYBNLXSCN-UHFFFAOYSA-N 0.000 description 2
- GNLHTHKIAWHDLB-UHFFFAOYSA-N 3-(benzenesulfonyl)-4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)CC1S(=O)(=O)C1=CC=CC=C1 GNLHTHKIAWHDLB-UHFFFAOYSA-N 0.000 description 2
- KYXYUBRSMMVUBO-UHFFFAOYSA-N 3-(benzenesulfonyl)-4-methylcyclohexan-1-one Chemical compound CC1CCC(=O)CC1S(=O)(=O)C1=CC=CC=C1 KYXYUBRSMMVUBO-UHFFFAOYSA-N 0.000 description 2
- BXKSAMBHWAXWHU-UHFFFAOYSA-N 3-(benzenesulfonyl)cyclohexan-1-one Chemical compound C1C(=O)CCCC1S(=O)(=O)C1=CC=CC=C1 BXKSAMBHWAXWHU-UHFFFAOYSA-N 0.000 description 2
- RKSNPTXBQXBXDJ-UHFFFAOYSA-N 4-methylcyclohex-2-en-1-one Chemical compound CC1CCC(=O)C=C1 RKSNPTXBQXBXDJ-UHFFFAOYSA-N 0.000 description 2
- ZYAODYITFKMKJC-UHFFFAOYSA-N 7-(benzenesulfonyl)-6-methyl-1,4-dioxaspiro[4.5]decane Chemical compound CC1C(S(=O)(=O)C=2C=CC=CC=2)CCCC11OCCO1 ZYAODYITFKMKJC-UHFFFAOYSA-N 0.000 description 2
- LJZHMMCSXAOUMJ-UHFFFAOYSA-N 7-(benzenesulfonyl)-8,8-dimethyl-1,4-dioxaspiro[4.5]decane Chemical compound C1C(S(=O)(=O)C=2C=CC=CC=2)C(C)(C)CCC21OCCO2 LJZHMMCSXAOUMJ-UHFFFAOYSA-N 0.000 description 2
- XOBVEZYLDYRXKM-UHFFFAOYSA-N 7-(benzenesulfonyl)-8-methyl-1,4-dioxaspiro[4.5]decane Chemical compound C1C(S(=O)(=O)C=2C=CC=CC=2)C(C)CCC21OCCO2 XOBVEZYLDYRXKM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000003790 Foot Ulcer Diseases 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229960002105 amrinone Drugs 0.000 description 2
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 2
- JEHKKBHWRAXMCH-UHFFFAOYSA-M benzenesulfinate Chemical compound [O-]S(=O)C1=CC=CC=C1 JEHKKBHWRAXMCH-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910001023 sodium amalgam Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- RXHONFUPUZJGQP-UHFFFAOYSA-N trimethyl-(4-methylcyclohexen-1-yl)oxysilane Chemical compound CC1CCC(O[Si](C)(C)C)=CC1 RXHONFUPUZJGQP-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WQRHISGXRFLGKQ-UHFFFAOYSA-N (2,6,6-trimethylcyclohexen-1-yl)methylsulfonylbenzene Chemical compound CC1(C)CCCC(C)=C1CS(=O)(=O)C1=CC=CC=C1 WQRHISGXRFLGKQ-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- VUUAVAQNQQXQSU-UHFFFAOYSA-N 10-[7-(benzenesulfonyl)-1,4-dioxaspiro[4.5]decan-7-yl]decan-1-ol Chemical compound C1C(CCCCCCCCCCO)(S(=O)(=O)C=2C=CC=CC=2)CCCC21OCCO2 VUUAVAQNQQXQSU-UHFFFAOYSA-N 0.000 description 1
- XFGANBYCJWQYBI-UHFFFAOYSA-N 11-bromoundecan-1-ol Chemical compound OCCCCCCCCCCCBr XFGANBYCJWQYBI-UHFFFAOYSA-N 0.000 description 1
- LKTNAAYQZJAXCJ-UHFFFAOYSA-N 2-methylcyclohex-2-en-1-one Chemical compound CC1=CCCCC1=O LKTNAAYQZJAXCJ-UHFFFAOYSA-N 0.000 description 1
- KOMZWLTUISSAIV-UHFFFAOYSA-N 3-(10-hydroxydecyl)-2-methylcyclohex-2-en-1-one Chemical compound OCCCCCCCCCCC1=C(C(CCC1)=O)C.OCCCCCCCCCCC1=C(C(CCC1)=O)C KOMZWLTUISSAIV-UHFFFAOYSA-N 0.000 description 1
- KZAHHZZXUVIIQI-UHFFFAOYSA-N 3-(10-hydroxydecyl)cyclohex-2-en-1-one Chemical compound OCCCCCCCCCCC1=CC(=O)CCC1 KZAHHZZXUVIIQI-UHFFFAOYSA-N 0.000 description 1
- UUVMGOIWPGHSQE-UHFFFAOYSA-N 3-(11-hydroxyundecyl)-2-methylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCO)CCCC1=O.CC1=C(CCCCCCCCCCCO)CCCC1=O UUVMGOIWPGHSQE-UHFFFAOYSA-N 0.000 description 1
- ZPXMRKNHLKICBX-UHFFFAOYSA-N 3-(13-hydroxytridecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCCO)C(C)(C)CCC1=O.CC1=C(CCCCCCCCCCCCCO)C(C)(C)CCC1=O ZPXMRKNHLKICBX-UHFFFAOYSA-N 0.000 description 1
- FGMAOXGOTRUOKJ-UHFFFAOYSA-N 3-(15-hydroxypentadecyl)-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound CC1=C(CCCCCCCCCCCCCCCO)C(C)(C)CCC1=O FGMAOXGOTRUOKJ-UHFFFAOYSA-N 0.000 description 1
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- HAUNPYVLVAIUOO-UHFFFAOYSA-N 4,4-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CCC(=O)C=C1 HAUNPYVLVAIUOO-UHFFFAOYSA-N 0.000 description 1
- XQVSDNVHXJFEJC-UHFFFAOYSA-N 5-(benzenesulfonyl)-2,3,4a,5,6,7,8,8a-octahydrobenzo[b][1,4]dioxine Chemical compound C1CCC2OCCOC2C1S(=O)(=O)C1=CC=CC=C1 XQVSDNVHXJFEJC-UHFFFAOYSA-N 0.000 description 1
- KZRWSVHOYCUWNM-UHFFFAOYSA-N 7-(benzenesulfonyl)-1,4-dioxaspiro[4.5]decane Chemical compound C=1C=CC=CC=1S(=O)(=O)C(C1)CCCC21OCCO2 KZRWSVHOYCUWNM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012645 Diabetic autonomic neuropathy Diseases 0.000 description 1
- 206010062356 Diabetic bullosis Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000003086 effect on acetylcholine Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- PDEDQSAFHNADLV-UHFFFAOYSA-M potassium;disodium;dinitrate;nitrite Chemical compound [Na+].[Na+].[K+].[O-]N=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PDEDQSAFHNADLV-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003591 thromboxane A2 derivatives Chemical class 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006145134A JP4986505B2 (ja) | 2005-05-26 | 2006-05-25 | 糖尿病性血管障害および呼吸障害予防および/または治療剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005153990 | 2005-05-26 | ||
| JP2005153990 | 2005-05-26 | ||
| JP2007517718 | 2005-11-24 | ||
| JP2007517718 | 2005-11-24 | ||
| JP2006145134A JP4986505B2 (ja) | 2005-05-26 | 2006-05-25 | 糖尿病性血管障害および呼吸障害予防および/または治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007230991A JP2007230991A (ja) | 2007-09-13 |
| JP2007230991A5 JP2007230991A5 (https=) | 2009-04-23 |
| JP4986505B2 true JP4986505B2 (ja) | 2012-07-25 |
Family
ID=38551939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006145134A Expired - Fee Related JP4986505B2 (ja) | 2005-05-26 | 2006-05-25 | 糖尿病性血管障害および呼吸障害予防および/または治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4986505B2 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4861560B2 (ja) * | 2001-02-19 | 2012-01-25 | 株式会社明治 | 糖尿病合併症治療剤 |
| ATE503471T1 (de) * | 2004-11-25 | 2011-04-15 | Meiji Dairies Corp | Mittel zur linderung von niereninsuffizienz |
-
2006
- 2006-05-25 JP JP2006145134A patent/JP4986505B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007230991A (ja) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10238620B2 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| JP3766591B2 (ja) | シクロヘキセノン長鎖アルコール及びこれを含有する医薬 | |
| US20090042971A1 (en) | Method of using low-dose doxepin for the improvement of sleep | |
| US20090042972A1 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| JP2001515058A5 (https=) | ||
| JP4469441B2 (ja) | 神経変性疾患の予防又は治療薬 | |
| US6906107B2 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | |
| JP4986505B2 (ja) | 糖尿病性血管障害および呼吸障害予防および/または治療剤 | |
| ES2355891T3 (es) | Derivado de ciclohexanona para el tratamiento de la neuropatía diabética. | |
| EP1839653B9 (en) | Therapeutic agent for sensory disorders | |
| CA2609595C (en) | Preventive and/or therapeutic agents for diabetic vascular disorders and respiratory disorders | |
| JP2002068973A (ja) | 幹細胞分化誘導促進剤 | |
| HK1112201A (en) | Therapeutic agent for sensory abnormality | |
| JP2001247461A (ja) | 糖尿病予防・改善剤 | |
| MC2048A1 (fr) | Utilisation pharmaceutique de composes naphtoquinoniques,formulations pharmaceutiques les contenant,nouveaux composes de ce type et leur procede de preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090309 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090309 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120126 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120308 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120416 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120424 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313114 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |